These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

803 related items for PubMed ID: 31915235

  • 1. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan.
    Suzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, Ito H, Kawamura M, Ogata Y, Ohtaka M, Nakahara M, Kawabe K.
    Gut; 2020 Jun; 69(6):1019-1026. PubMed ID: 31915235
    [Abstract] [Full Text] [Related]

  • 2. Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan.
    Gotoda T, Kusano C, Suzuki S, Horii T, Ichijima R, Ikehara H.
    J Gastroenterol; 2020 Oct; 55(10):969-976. PubMed ID: 32666199
    [Abstract] [Full Text] [Related]

  • 3. Vonoprazan Dual or Triple Therapy Versus Bismuth-Quadruple Therapy as First-Line Therapy for Helicobacter pylori Infection: A Three-Arm, Randomized Clinical Trial.
    Cheung KS, Lyu T, Deng Z, Han S, Ni L, Wu J, Tan JT, Qin J, Ng HY, Leung WK, Seto WK.
    Helicobacter; 2024 Oct; 29(5):e13133. PubMed ID: 39244723
    [Abstract] [Full Text] [Related]

  • 4. The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication.
    Sue S, Kuwashima H, Iwata Y, Oka H, Arima I, Fukuchi T, Sanga K, Inokuchi Y, Ishii Y, Kanno M, Terada M, Amano H, Naito M, Iwase S, Okazaki H, Komatsu K, Kokawa A, Kawana I, Morimoto M, Saito T, Kunishi Y, Ikeda A, Takahashi D, Miwa H, Sasaki T, Tamura T, Kondo M, Shibata W, Maeda S.
    Intern Med; 2017 Oct; 56(11):1277-1285. PubMed ID: 28566587
    [Abstract] [Full Text] [Related]

  • 5. Vonoprazan-based therapies versus PPI-based therapies in patients with H. pylori infection: Systematic review and meta-analyses of randomized controlled trials.
    Liu L, Shi H, Shi Y, Wang A, Guo N, Li F, Nahata MC.
    Helicobacter; 2024 Oct; 29(3):e13094. PubMed ID: 38790090
    [Abstract] [Full Text] [Related]

  • 6. Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori.
    Bunchorntavakul C, Buranathawornsom A.
    J Gastroenterol Hepatol; 2021 Dec; 36(12):3308-3313. PubMed ID: 34622504
    [Abstract] [Full Text] [Related]

  • 7. Seven-Day Vonoprazan-Based Triple Therapy as First-Line Helicobacter pylori Treatment in Comparison With Extended Sequential Therapy: A Randomized Controlled Trial.
    Chiu YT, Lee FJ, Kuo CY, Chen YT, Lin YC, Liang KS, Wu CY, Lin RT, Lin JT, Chang CY.
    Helicobacter; 2024 Dec; 29(4):e13129. PubMed ID: 39164808
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility.
    Okubo H, Akiyama J, Kobayakawa M, Kawazoe M, Mishima S, Takasaki Y, Nagata N, Shimada T, Yokoi C, Komori S, Kimura K, Hisada Y, Iwata E, Watanabe K, Yanagisawa N, Shiroma S, Shimomura A, Okahara K, Cho H, Uemura N.
    J Gastroenterol; 2020 Nov; 55(11):1054-1061. PubMed ID: 32930864
    [Abstract] [Full Text] [Related]

  • 12. Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.
    Tanabe H, Yoshino K, Ando K, Nomura Y, Ohta K, Satoh K, Ichiishi E, Ishizuka A, Otake T, Kohgo Y, Fujiya M, Okumura T.
    Ann Clin Microbiol Antimicrob; 2018 Jun 28; 17(1):29. PubMed ID: 29950163
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori.
    Furuta T, Yamade M, Kagami T, Uotani T, Suzuki T, Higuchi T, Tani S, Hamaya Y, Iwaizumi M, Miyajima H, Umemura K, Osawa S, Sugimoto K.
    Digestion; 2020 Jun 28; 101(6):743-751. PubMed ID: 31434101
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of Vonoprazan for Helicobacter pylori Eradication.
    Kiyotoki S, Nishikawa J, Sakaida I.
    Intern Med; 2020 Jan 15; 59(2):153-161. PubMed ID: 31243237
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature.
    Tanabe H, Ando K, Sato K, Ito T, Goto M, Sato T, Fujinaga A, Kawamoto T, Utsumi T, Yanagawa N, Ichiishi E, Otake T, Kohgo Y, Nomura Y, Ueno N, Sugano H, Kashima S, Moriichi K, Fujiya M, Okumura T.
    Dig Dis Sci; 2017 Nov 15; 62(11):3069-3076. PubMed ID: 28664410
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis.
    Zhang WL, Lin BS, Li YY, Ding YM, Han ZX, Ji R.
    Digestion; 2023 Nov 15; 104(4):249-261. PubMed ID: 37015201
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.